Clinical trial
A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)
NCT00439803 · AlphaVax, Inc., Industry · Completed
Key facts
| NCT number | NCT00439803 |
|---|---|
| Title | A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) |
| Official title | A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers |
| Acronym | CMV |
| Lead sponsor | AlphaVax, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Biological |
| Interventions | AVX601, Placebo |
| Enrollment | 40 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Feb 26, 2007 |
| Last update posted | Nov 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: